Efficacy and Safety of Risankizumab in Crohn's Disease: A Systematic Review and Meta-Analysis of Randomized Trials and Real-World Evidence.

Dig Dis SciMay 18, 2026 (epub)
Clinical ResearchGastroenterologyOpen access

Alaa Abdrabou Abouelmagd, Mazen Negmeldin Yassin, Dina Essam Abo-Elnour et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the efficacy and safety of Risankizumab (RZB) in patients with moderate-to-severe Crohn's disease, incorporating data from five randomized controlled trials and nine observational studies (n=3275). RZB significantly improved clinical remission rates at induction (RR: 1.90) and maintenance (RR: 1.34) compared to placebo, with favorable safety outcomes.

Key findings

  • RZB increased clinical remission rates at induction (RR: 1.90) and maintenance (RR: 1.34) compared to placebo.
  • Endoscopic remission was significantly higher with RZB at induction (RR: 3.25) and maintenance (RR: 2.04).
  • Pooled real-world evidence showed clinical remission rates of 57% at 12 weeks and 44% at 1 year.

Why it matters

The findings highlight Risankizumab's effectiveness in achieving and maintaining remission in Crohn's disease, particularly in patients who have failed previous biologic therapies. This information is crucial for clinicians managing complex cases.

Source

PubMed · PMID 42151576Free full text on PubMed Central

Published in Dig Dis Sci. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchPreventive Medicine / Public Health

2025 National Guidelines on the Mediterranean Diet: Executive Summary of a Joint Report by Italian Scientific Societies and the National Institute of Health Task Force on Clinical Practice Guidelines.

This systematic review and practice guideline, developed by a multidisciplinary panel using NUTRIGRADE, assessed Mediterranean diet evidence across nine health domains and one economic domain.

Nutr RevNov 12, 2026Read summary
Clinical ResearchOrthopedic Surgery

Prevention of Venous Thromboembolism after Total Hip or Knee Replacement.

This multicenter randomized comparative-effectiveness noninferiority trial compared 30 days of aspirin, warfarin, or rivaroxaban for VTE prophylaxis after elective total hip or knee arthroplasty.

N Engl J MedNov 12, 2026Read summary
Clinical ResearchAnesthesiology

Effect of discontinuing antihypertensives on perioperative hypotension in older patients before non-cardiac surgery: multicentre, randomised, double blind, controlled trial.

This multicentre, randomised, double blind, placebo controlled trial assessed whether withholding ACE inhibitors or ARBs on the morning of surgery reduces perioperative hypotension in older adults undergoing non-cardiac…

BMJNov 11, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.